Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001628280-26-034204
Filing Date
2026-05-12
Accepted
2026-05-12 17:16:10
Documents
66
Period of Report
2026-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q abos-20260331.htm   iXBRL 10-Q 811392
2 EX-31.1 abos-20260331x10qxexx311.htm EX-31.1 10516
3 EX-31.2 abos-20260331x10qxexx312.htm EX-31.2 10479
4 EX-32.1 abos-20260331x10qxexx321.htm EX-32.1 4944
5 EX-32.2 abos-20260331x10qxexx322.htm EX-32.2 4987
  Complete submission text file 0001628280-26-034204.txt   5926086

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT abos-20260331.xsd EX-101.SCH 44707
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT abos-20260331_cal.xml EX-101.CAL 74768
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT abos-20260331_def.xml EX-101.DEF 212528
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT abos-20260331_lab.xml EX-101.LAB 630366
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT abos-20260331_pre.xml EX-101.PRE 423504
70 EXTRACTED XBRL INSTANCE DOCUMENT abos-20260331_htm.xml XML 757850
Mailing Address 1210-1220 WASHINGTON STREET SUITE 210 NEWTON MA 02465
Business Address 1210-1220 WASHINGTON STREET SUITE 210 NEWTON MA 02465 617-344-4190
Acumen Pharmaceuticals, Inc. (Filer) CIK: 0001576885 (see all company filings)

EIN.: 364108129 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-40551 | Film No.: 26969860
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)